Investment Thesis
Alector is a pre-revenue stage biotech company with severe operational losses (-$142.9M net loss on only $21.0M revenue) and dramatically negative profitability metrics (net margin of -679.2%). The company is burning cash at an unsustainable rate (-$184.1M operating cash flow) with only 3.6 years of cash runway at current burn, indicating imminent financing risk or liquidation pressure.
Strengths
- Strong liquidity position with $65.8M cash and 3.83x current ratio providing near-term operational flexibility
- Modest long-term debt burden with 0.33x debt-to-equity ratio limiting financial leverage risk
- Recent insider activity (8 Form 4 filings in 90 days) suggests active management engagement
Risks
- Catastrophic cash burn rate of $184M annually with only $65.8M cash remaining - company faces critical funding necessity within 4 quarters
- Revenue generation appears minimal ($21M) and flat YoY, insufficient to offset R&D/operating expenses in biotech development stage
- Operating losses of $156M with net margin of -679% indicate no clear path to profitability without significant revenue inflection or major asset sale
- Negative free cash flow of -$184.1M demonstrates company cannot fund operations from internal operations and is entirely dependent on external financing
Key Metrics to Watch
- Cash balance depletion rate and runway until next financing event
- Clinical trial progress and pipeline advancement toward revenue-generating approvals
- Quarterly revenue growth trajectory and any evidence of commercial traction
- Operating expense burn rate and management's cost control actions
Financial Metrics
Revenue
21.0M
Net Income
-142.9M
EPS (Diluted)
$-1.39
Free Cash Flow
-184.1M
Total Assets
293.2M
Cash
65.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-741.3%
Net Margin
-679.2%
ROE
-466.3%
ROA
-48.7%
FCF Margin
-874.7%
Balance Sheet & Liquidity
Current Ratio
3.83x
Quick Ratio
3.83x
Debt/Equity
0.33x
Debt/Assets
89.5%
Interest Coverage
N/A
Long-term Debt
10.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T18:04:22.647992 |
Data as of: 2025-12-31 |
Powered by Claude AI